Polypharmacy in patients with schizophrenia

Journal of Clinical Psychiatry

Volumn 64, Issue 9, 2003, Pages 984-989

  McCue, Robert E ^a   Waheed, Rubina ^b   Urcuyo, Leonel ^b  

^a WOODHULL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZATROPINE; BENZATROPINE MESILATE; BUSPIRONE; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; DIPHENHYDRAMINE; FLUOXETINE; FLUPHENAZINE; GABAPENTIN; HALOPERIDOL; HYDROXYZINE EMBONATE; LORAZEPAM; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TIOTIXENE; TRAZODONE; VALPROATE SEMISODIUM;

ADULT; ARTICLE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0141605490     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0902     Document Type: Article

References (21)

1. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 1997;154(suppl 4):1-63
2. McEvoy JP, Scheifler PL, Frances A, eds. Expert Consensus Guideline Series: Treatment of Schizophrenia 1999. J Clin Psychiatry 1999;60(suppl II):1-80
3. Wilson WH, Ban TA, Guy W. Pharmacotherapy of chronic hospitalized schizophrenics: prescriptive practices. Pharmacopsychiatry 1985;14: 75-82
4. Takei N, Inagaki A. Polypharmacy for psychiatric treatments in Japan [letter]. Lancet 2002;360:649
5. Procyshyn RM, Kennedy NB, Tse G, et al. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001;46:334-339
6. Stahl SM. Selecting an atypical antipsychotic by combining experience with guidelines from clinical trials. J Clin Psychiatry 1999;60(suppl 10): 31-41
7. Covell NH, Jackson CT, Evans AC, et al. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002;28:17-29
8. Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration-New York metropolitan region. Schizophr Bull 2002;28:31-42
9. Mantonakis I, Kattan K, Zervas IM. Risperidone augmentation of clozapine and olanzapine for refractory schizophrenia. Eur Neuropsychopharmacol 1998;8(suppl 2):S233
10. Waring EW, Devin PG, Dewan V. Treatment of schizophrenia with antipsychotics in combination. Can J Psychiatry 1999;44:189-190
11. Kennedy NB, Procyshyn RM. Rational antipsychotic polypharmacy. Can J Clin Pharmacol 2000;7:155-159
12. Lerner V, Chudakova B, Kravets S, et al. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report. Clin Neuropharmacol 2000;23:284-286
13. Rhoads E. Polypharmacy of 2 atypical antipsychotics [letter]. J Clin Psychiatry 2000;61:678-679
14. de Groot IW, Heck AH, van Harten PN. Addition of risperidone to clozapine therapy in chronically psychotic inpatients [letter]. J Clin Psychiatry 2001;62:129-130
15. Taylor CG, Flynn SW, Altman S, et al. An open trial of risperidone augmentation of partial response to clozapine. Schizophr Res 2001; 48:155-158
16. Waddington JL, Youseff HA, Kinsella A. Mortality in schizophrenia. Br J Psychiatry 1998;173:325-329
17. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia: a review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002;106:323-330
18. Canales PL, Olsen J, Miller AL, et al. Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia. CNS Drugs 1999;12:179-188
19. Freeman MP, Stoll AL. Mood stabilizer combinations: a review of safety and efficacy. Am J Psychiatry 1998;155:12-21
20. 2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001;50:873-883
21. Dufresne RL. Issues in polypharmacotherapy: focus on depression in schizophrenia. Psychopharmacol Bull 1995;31:789-796